Absci Corporation names industry veteran Gerry Muhle as Chief Commercial Officer to drive the commercialization of its generative AI-designed pipeline, including the upcoming ABS-201 hair-regrowth program.
The company appointed Gerry Muhle as Chief Commercial Officer to build the commercial strategy for ABS-201 ahead of anticipated 13-week interim proof-of-concept data in December 2026. This is a personnel/organizational announcement without quantified financials, so it should not materially move the stock; the real near-term driver remains the December 2026 data readout.
Absci Corporation has appointed Gerry Muhle as Chief Commercial Officer to spearhead the commercial strategy for its pipeline, specifically focusing on the ABS-201 therapeutic. Muhle, formerly a senior executive at Galderma, brings over 25 years of experience in prescription medicine and consumer brand development. The company expects to report 13-week interim proof-of-concept data for ABS-201 in December 2026.